(Q42274057)

English

Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab

scientific article published on 25 August 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Maria Inmaculada Dominguez-Mozo

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Marta Garcia-Montojo

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Virginia De Las Heras

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Angel Garcia-Martinez

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ana María Arias-Leal

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ignacio Casanova

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Rafael Arroyo

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Roberto Alvarez-Lafuente

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

25 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Neuroimmune Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1277-1286

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Asymptomatic reactivation of JC virus in patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

High incidence of urinary JC virus excretion in nonimmunosuppressed older patients

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Characterization of JC human polyomavirus infection in a Portuguese population.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-013-9496-Y

21 January 2018

Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23979860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/23979860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23979860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JCV detection in multiple sclerosis patients treated with natalizumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23979860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Dynamics of Herpesvirus and Polyomavirus Reactivation and Shedding in Healthy Adults: A 14‐Month Longitudinal Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23979860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11481-013-9496-Y

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42274057&oldid=2205192701"